OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bekaii-Saab on Resistance to Targeted Therapy in CRC

December 27th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses resistance to targeted therapy in the treatment of patients with colorectal cancer.

Dr. Corcoran on Future of Liquid Biopsies in GI Cancers

December 27th 2018

Ryan B. Corcoran, MD, PhD, clinical researcher, Massachusetts General Hospital, assistant professor of medicine, Harvard Medical School, discusses the future role of liquid biopsies in gastrointestinal cancers.

Dr. Andreeff Discusses Promise of Venetoclax in AML

December 21st 2018

Michael Andreeff, MD, PhD, chair of genetics, professor of medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of venetoclax in acute myeloid leukemia.

Dr. Tripathy Discusses Pertuzumab in HER2+ Breast Cancer

December 21st 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of pertuzumab in HER2-positive breast cancer.

Dr. Strickler on Applications for Liquid Biopsies in GI Cancer

December 21st 2018

John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses applications for liquid biopsies in gastrointestinal cancer.

Dr. Jagannath on Cancer Proliferation in Multiple Myeloma

December 21st 2018

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses cancer proliferation in multiple myeloma.

Augmenting T-Cell Immunity in Pancreatic Cancer

December 21st 2018

Stephanie K. Dougan, PhD, assistant professor, Microbiology and Immunobiology, Division of Immunology, Harvard Medical School, researcher, Dana-Farber Cancer Institute, discusses ways of augmenting T-cell immunity in pancreatic cancer.

Dr. Phillips on Emerging Combination in MCL

December 20th 2018

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses an emerging combination in the treatment of patients with mantle cell lymphoma.

Dr. Overman on Next Steps With Immunotherapy in mCRC

December 20th 2018

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses next steps with immunotherapy in the treatment of patients with metastatic colorectal cancer.

Dr. Lenz on Potential for Immunotherapy in mCRC

December 20th 2018

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the potential for immunotherapy in metastatic colorectal cancer.

Dr. Sugarbaker on Perioperative Chemotherapy in Gastrointestinal Cancer

December 20th 2018

Paul H. Sugarbaker, MD, FACS, FRCS, chief of the peritoneal surface malignancy program and director of the Center for Gastrointestinal Malignancies at MedStar Washington Hospital Center, discusses the use of perioperative chemotherapy in the treatment of patients with gastrointestinal (GI) cancer.

Dr. Hamid on the FDA Approval of Pembrolizumab in Merkel Cell Carcinoma

December 20th 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

Dr. Ghobadi on Ways of Reducing the Cost of CAR T-Cell Therapy

December 20th 2018

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses ways of reducing the cost of chimeric antigen receptor (CAR) T-cell therapy.

Dr. English on Mirvetuximab Soravtansine in Ovarian Cancer

December 20th 2018

Diana P. English, MD, a gynecologic oncologist at Stanford Hospital and Clinics, discusses the development of the antibody drug conjugate (ADC) mirvetuximab soravtansine in ovarian cancer.

Dr. Corcoran on Benefits/Limitations of Liquid Biopsies in GI Cancer

December 19th 2018

Ryan B. Corcoran, MD, PhD, clinical researcher, Massachusetts General Hospital, assistant professor of medicine, Harvard Medical School, discusses the benefits and limitations of liquid biopsies in gastrointestinal cancer.

Dr. Bekaii-Saab on Challenges With Precision Medicine in CRC

December 19th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the challenges of bringing a precision medicine approach into the clinic in colorectal cancer.

Dr. George Discusses Treatment of Uterine Leiomyosarcoma

December 19th 2018

Suzanne George, MD, assistant professor of Medicine, Harvard Medical School, clinical director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses the current treatment for patients with uterine leiomyosarcoma.

Dr. George on Sequencing in Renal Cell Carcinoma

December 18th 2018

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses sequencing in renal cell carcinoma (RCC).

Dr. Chari on PVd for Relapsed Patients With Multiple Myeloma

December 18th 2018

Ajai Chari, MD, associate professor of Medicine, Hematology and Medical Oncology, at Mount Sinai Hospital, discusses the use of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (PVd) for relapsed patients with multiple myeloma.

Dr. Desai on Immunotherapy in Patients With NSCLC and Low PD-L1 Expression

December 18th 2018

Amishi Desai, MD, assistant professor of medicine at Upstate University Hospital, discusses the use of immunotherapy in patients with non–small cell lung cancer (NSCLC) with PD-L1 expression less than 1%.